- Pfizer ( NYSE: PFE ) has agreed to buy Global Blood Therapeutics ( GBT ) for $5.4B in cash, The Wall Street Journal reported on Monday citing people familiar with matter ahead of a formal announcement from the companies.
- According to the people, Pfizer is expected to pay $68.50 per share in cash for Global Blood ( GBT ) which markets sickle cell disease therapy Oxbryta tablets.
- Last Friday, The Journal reported that the companies were in advanced talks to form a deal sending Global Blood ( GBT ) shares to close ~33% higher.
For further details see:
Pfizer inks $5.4B deal to acquire SCD drug maker Global Blood Therapeutics – WSJ